OOIR: Observatory of International Research

Papers

(The H4-Index of Biochemical Pharmacology is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective	670
The growth of siRNA-based therapeutics: Updated clinical studies	248
Detection of Viral Infections by Innate Immunity	216
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine	134
Sleep timing, chronotype and social jetlag: Impact on cognitive abilities and psychiatric disorders	101
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro	96
Animal toxins — Nature’s evolutionary-refined toolkit for basic research and drug discovery	96
Targeting tumor-associated macrophages as an antitumor strategy	86
Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1	85
Drug uptake-based chemoresistance in breast cancer treatment	84
Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease	83
P2X7 receptor and the NLRP3 inflammasome: Partners in crime	81
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management	79
Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches	77
Therapeutic potential of targeting mitochondrial dynamics in cancer	75
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action	74
White adipose tissue dysfunction in obesity and aging	71
Polo-like kinase 1 (PLK1) signaling in cancer and beyond	69
The relevance of daylight for humans	68
Berberine suppresses colon cancer cell proliferation by inhibiting the SCAP/SREBP-1 signaling pathway-mediated lipogenesis	68
Recent progress on targeting ferroptosis for cancer therapy	65
Mechanisms of ketamine and its metabolites as antidepressants	65
Minocycline promotes functional recovery in ischemic stroke by modulating microglia polarization through STAT1/STAT6 pathways	64
Obesity II: Establishing causal links between chemical exposures and obesity	64
Circadian rhythm in pharmacokinetics and its relevance to chronotherapy	62

Ferroptosis and its potential as a therapeutic target	62
Vitamin D attenuates lung injury via stimulating epithelial repair, reducing epithelial cell apoptosis and inhibits TGF-β induced epithelial to mesenchymal transition	62
Alzheimer’s disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?	60
Advances in the molecular mechanisms of NLRP3 inflammasome activators and inactivators	60
Obesity I: Overview and molecular and biochemical mechanisms	60
Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics	59
Lactobacillus rhamnosus GG supplementation modulates the gut microbiota to promote butyrate production, protecting against deoxynivalenol exposure in nude mice	58
Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction	58
Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms	52
New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers	52
Reversal of endothelial dysfunction by nicotinamide mononucleotide via extracellular conversion to nicotinamide riboside	52
Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance	51
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking	50
Omentin-1 protects against high glucose-induced endothelial dysfunction via the AMPK/PPARδ signaling pathway	50
Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer’s disease	50
The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations	49
Melatonin fine-tunes intracellular calcium signals and eliminates myocardial damage through the IP3R/MCU pathways in cardiorenal syndrome type 3	49
Molecular pharmacology of P2Y receptor subtypes	49
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective	49
COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials	48
Antisense drug discovery and development technology considered in a pharmacological context	48
Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function	47
Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: Opportunities for novel therapeutics development	47